Albumedix A/S has appointed Dr Giles Campion as Chief Medical Officer (CMO). Giles brings with him more than 25 years' experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe. He will be responsible for leading Albumedix's global development efforts, establishing a proprietary pipeline, as well as strengthening the company's partnered drug pipeline. He will join Albumedix's executive management team, reporting to the company's CEO Peter Rosholm.

Prior to joining Albumedix, Giles was Senior Vice President of Research and Development and CMO at Prosensa Holdings and then Group Vice President, Neuromuscular Franchise at Biomarin following the Prosensa acquisition. Previously he had held positions such as Global Head of Clinical Research and Development at General Electric Healthcare and European Head of Exploratory Clinical Development at Novartis. With experience across multiple therapeutic areas, most recently in orphan neuromuscular disorders, he has overseen global and regional filing and approvals of new products in cardiovascular diseases, diabetes, oncology, neurodegenerative diseases and hormone deficiency. During his career he has been responsible for the development of over 40 therapeutics and diagnostic agents.